Discover 117 paid clinical trials in Fort Wayne, Indiana. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.
Filter
2
Filter results
Results: 117
Phase 2/3 Adaptive Study of VX-147 in Adult and Pediatric Participants With APOL1-Mediated Proteinuric Kidney Disease
for
Proteinuric Kidney Disease
Location: Fort Wayne IN, Ann Arbor MI, Chicago IL, Columbus OH,
Sponsor: Vertex Pharmaceuticals Incorporated
Sex: All
Age: 10 - 65
Code: NCT05312879
Phase2, Phase3, Recruiting
New
Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
for
B-cell Lymphoma, Chronic Lymphocytic Leukemia,
Location: Fort Wayne IN, Indianapolis IN, Nashville TN,
Sponsor: Nurix Therapeutics, Inc.
Sex: All
Age: 18+
Code: NCT07516093
Phase3, Recruiting
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
for
Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion,
Location: Fort Wayne IN, Lansing MI, Farmington Hills MI,
Sponsor: Bayer
Sex: All
Age: 0+
Code: NCT04142437
Recruiting
BostonGene and Exigent Genomic INsight Study
for
Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Sarcoma
Location: Fort Wayne IN, Rogers AR, Tulsa OK, Houston TX,
Sponsor: BostonGene
Sex: All
Age: 18+
Code: NCT06272864
Recruiting
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling
for
HER2-negative Breast Cancer
Location: Fort Wayne IN, Dayton OH, Marion OH, Ann Arbor MI,
Sponsor: NSABP Foundation Inc
Sex: Female
Age: 18+
Code: NCT03412643
Phase2, Recruiting
Interested in new trials?
Get alerts for new trials in your area by subscribing now
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
for
Non Small Cell Lung Cancer, Triple Negative Breast Cancer,
Location: Fort Wayne IN, Buffalo NY, Nashville TN, Athens GA,
Sponsor: Compass Therapeutics
Sex: All
Age: 18+
Code: NCT06150664
Phase1, Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
for
Mantle Cell Lymphoma, B Cell Lymphoma
Location: Fort Wayne IN, Ann Arbor MI, Grand Rapids MI,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06742996
Phase3, Recruiting
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
for
Colorectal Neoplasms
Location: Fort Wayne IN, Ann Arbor MI, Sandusky OH,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06662786
Phase3, Recruiting
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
for
B-cell Malignancy, Chronic Lymphocytic Leukemia,
Location: Fort Wayne IN, Maumee OH, Chicago IL, Milwaukee WI,
Sponsor: Carna Biosciences, Inc.
Sex: All
Age: 18+
Code: NCT05602363
Phase1, Recruiting
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
for
Large B-cell Lymphoma
Location: Fort Wayne IN, Indianapolis IN, Cincinnati OH,
Sponsor: Allogene Therapeutics
Sex: All
Age: 18+
Code: NCT06500273
Phase2, Recruiting
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
for
Carcinoma, Non-Small-Cell Lung
Location: Fort Wayne IN, Noblesville IN, Ann Arbor MI,
Sponsor: Janssen Research & Development, LLC
Sex: All
Age: 18+
Code: NCT06667076
Phase2, Recruiting
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
Location: Fort Wayne IN, St Louis MO, Westwood KS, Boston MA,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT06697184
Phase1, Phase2, Recruiting
BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease
for
HR+/HER2- Breast Cancer
Location: Fort Wayne IN, Indianapolis IN, Dayton OH, Hinsdale IL,
Sponsor: BeOne Medicines
Sex: All
Age: 18+
Code: NCT07492641
Phase3, Recruiting
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
for
Non-small Cell Lung Cancer (NSCLC)
Location: Fort Wayne IN, Chicago IL, Detroit MI, Cincinnati OH,
Sponsor: Bristol-Myers Squibb
Sex: All
Age: 18+
Code: NCT07361497
Phase3, Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
for
Extensive-stage Small-cell Lung Cancer
Location: Fort Wayne IN, Kettering OH, Cincinnati OH, Niles IL,
Sponsor: BioNTech SE
Sex: All
Age: 18+
Code: NCT06712355
Phase3, Recruiting
A Study of HS-20110 in Participants With Advanced Solid Tumors
for
Solid Tumors
Location: Fort Wayne IN, Fairfax VA, Huntersville NC, Irving TX,
Sponsor: Hansoh BioMedical R&D Company
Sex: All
Age: 18+
Code: NCT06892379
Phase1, Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
for
Breast Neoplasms, Triple Negative Breast Neoplasms,
Location: Fort Wayne IN, Indianapolis IN, Cincinnati OH,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06966700
Phase3, Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
for
Leukemia, Lymphocytic, Chronic, B-Cell,
Location: Fort Wayne IN, Charlottesville VA, Bethesda MD,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT05947851
Phase3, Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
for
Diffuse Large B-Cell Lymphoma
Location: Fort Wayne IN, Ann Arbor MI, Grand Rapids MI,
Sponsor: Merck Sharp & Dohme LLC
Sex: All
Age: 18+
Code: NCT06717347
Phase3, Recruiting
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
for
Carcinoma, Non-Small Cell Lung,
Location: Fort Wayne IN, Indianapolis IN, Crown Point IN,
Sponsor: Seagen, a wholly owned subsidiary of Pfizer